Zogenix soars on 2015 hopes for abuse-deterrent Zohydro
This article was originally published in Scrip
Executive Summary
Zogenix investors drove shares up 20% on 2 July after the company expressed confidence it would be ready to submit an application to the FDA by October for a harder-to-abuse version of the firm's controversial single-entity extended-release hydrocodone Zohydro ER – with the potential the new capsule formulation could be on the US market by early 2015.